A citation-based method for searching scientific literature

John Dupré, Margaret T Behme, Thomas J McDonald. J Clin Endocrinol Metab 2004
Times Cited: 92

List of shared articles

Times cited

Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver.
Dan Zheng, Viorica Ionut, Vahe Mooradian, Darko Stefanovski, Richard N Bergman. Diabetes 2009

The GLP-1 system as a therapeutic target.
C Mark B Edwards. Ann Med 2005

Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists.
Urd Kielgast, Jens J Holst, Sten Madsbad. Curr Diabetes Rev 2009

Neonatal exendin-4 treatment reduces oxidative stress and prevents hepatic insulin resistance in intrauterine growth-retarded rats.
Elisabeth L Raab, Patricia M Vuguin, Doris A Stoffers, Rebecca A Simmons. Am J Physiol Regul Integr Comp Physiol 2009

Is exenatide a useful addition to diabetes therapy?
Nasser E Mikhail. Endocr Pract 2006

Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates neointimal hyperplasia after vascular injury.
Yoichiro Hirata, Hirotsugu Kurobe, Chika Nishio, Kimie Tanaka, Daiju Fukuda, Etsuko Uematsu, Sachiko Nishimoto, Takeshi Soeki, Nagakatsu Harada, Hiroshi Sakaue,[...]. Eur J Pharmacol 2013

Exenatide can reduce glucose independent of islet hormones or gastric emptying.
Viorica Ionut, Dan Zheng, Darko Stefanovski, Richard N Bergman. Am J Physiol Endocrinol Metab 2008

Anthony H Barnett. Drugs Today (Barc) 2005